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Corticotropin releasing factor (CRF) is a major mediator of central nervous system
responses to stressors, including alterations in wakefulness and sleep. However, its role
in mediating stress-induced alterations in sleep has not been fully delineated. In this
study, we assessed the role of CRF and the non-specific CRF antagonist, astressin
(AST), in regulating changes in sleep produced by signaled, escapable shock (SES)
and signaled inescapable shock (SIS), two stressors that can increase or decrease
sleep, respectively. Male BALB/cJ mice were surgically implanted with transmitters
(DataSciences ETA10-F20) for recording EEG, activity and core body temperature by
telemetry and a cannula for intracerebroventricular (ICV) microinjections. After baseline
(Base) sleep recording, mice were presented tones (90 dB, 2 kHz) that started 5.0 s
prior to and co-terminated with footshock (0.5mA; 5.0 s maximum duration). SES mice
(n = 9) always received shock but could terminate it by moving to the non-occupied
chamber in a shuttlebox. Yoked SIS mice (n = 9) were treated identically, but could not
alter shock duration. Training with SES or SIS was conducted over 2 days to stabilize
responses. Afterwards, the mice received saline, CRF [0.4µg (0.42mM) or AST (1.0µg
(1.4mM)] prior to SES or SIS. Sleep was analyzed over 20 h post-stress recordings.
After administration of saline, REM was significantly greater in SES mice than in SIS mice
whereas after CRF or AST, REM was similar in both groups. Total 20 h NREM did not
vary across condition or group. However, after administration of saline and CRF, NREM
episode duration was significantly decreased, and NREM episode number significantly
increased, in SIS mice compared to SES animals. SES and SIS mice showed similar
stress induced hyperthermia (SIH) across all conditions. These data demonstrate that
CRF can mediate stress-induced changes in sleep independently of SIH, an index of
hypothalamic-pituitary-adrenal axis activation.
Keywords: corticotropin releasing factor, stress, predictability, controllability, escape learning, stress-induced
hyperthermia
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Introduction
Corticotropin releasing factor (CRF) is a major mediator of
central nervous system responses to stressors (Koob and Bloom,
1985; Heinrichs et al., 1995; Koob, 1999; Koob and Heinrichs,
1999; Bakshi and Kalin, 2000; Deussing and Wurst, 2005)
including alterations in wakefulness and sleep (González and
Valatx, 1998; Chang and Opp, 2002). CRF antagonists attenuate
behavioral responses to stress (e.g., Aloisi et al., 1999; Basso et al.,
1999; Deak et al., 1999) whereas intracerebroventricular (ICV)
administration of CRF can produce many of the signs associated
with anxiety in humans, including increased wakefulness (Ehlers
et al., 1986;Marrosu et al., 1990; Chang andOpp, 1998), increased
activity, and an exaggerated startle response (Swerdlow et al.,
1986; Heilig et al., 1994). In the absence of stressors, CRF
contributes to the regulation of spontaneous waking (Opp, 1995,
1997; Chang and Opp, 1998, 2001).
CRF has been implicated in the control of rapid eyemovement
sleep (REM) (González and Valatx, 1997) and some authors have
argued that CRF promotes REM. However, there actually have
been few studies examining the role of CRF in regulating stress-
induced alterations in sleep, and these have yielded conflicting
data. This is exemplified with the work on restraint stress and
sleep. For example, González and Valatx (1997) reported that the
ICV administration of the broad CRF antagonist, αHelCRF (α-
helical CRF9-41), prior to restraint stress at the beginning of the
dark period prevented the subsequent increase in REM that can
occur after restraint (e.g., Rampin et al., 1991; Bonnet et al., 1997;
Meerlo et al., 2001), but did not alter spontaneous REM, NREM,
or wakefulness in non-stressed animals. In contrast, Chang and
Opp found no effect of restraint stress applied at the beginning of
the dark period on subsequent sleep, and also found no effect of
the non-specific CRF antagonist, astressin (AST), on sleep after
restraint (Chang and Opp, 2002). There also are conflicting data
on the effects of CRF on REM recovery after sleep deprivation.
CRF antagonists administered during sleep deprivation reduce
recovery REM in rats (González and Valatx, 1998) and mice
(Kimura et al., 2010) whereas the repeated administration of CRF
during the actual recovery period blocked the increase in REM in
sleep-deprived humans (Schüssler et al., 2006).
Fear conditioning with inescapable shock (IS), an
uncontrollable stressor, and the presentation of fearful contexts
and cues associated with IS are followed by significant reductions
in REM that occur in the first few hours after exposure (Sanford
et al., 2003a,b,c; Pawlyk et al., 2005). In mice trained with IS,
ICV administration of CRF enhances the reduction in REM
following fearful contexts whereas ICV administration of AST
attenuates fear-induced reductions in REM (Yang et al., 2009). By
comparison, training with escapable shock (ES), and reminders
of ES, can produce significant enhancements in post-stress REM
(Sanford et al., 2010). Microinjections of either saline or AST
prior to ES training produce similar, significant enhancements
in post-stress REM relative to a non-shocked handling control
condition whereas the increases in REM are blocked by
pre-training treatment with CRF (Yang et al., 2011b). Direct
comparisons of the effects of manipulating CRF on alterations in
sleep associated with controllable and uncontrollable stress have
not been made; however, the results to date are consistent with a
suppressing effect of CRF on REM after exposure to stress.
In summary, studies administering antagonists prior to or
during the presentation of stressors or sleep deprivation have
led to conclusions that CRF can promote REM whereas studies
administering CRF in stress paradigms suggest that that it can
suppress REM. In the current study, we compared the effects
of CRF and AST on stress-induced alterations in sleep in mice
trained with auditory-signaled variants of ES and IS (SES and SIS,
respectively), which also produce equivalent physical stress but
directionally different alterations in REM (Yang et al., 2011a). We
concurrently examined stress-induced hyperthermia (SIH), an
increase in core body temperature induced by both physiological
and psychological stress (Vinckers et al., 2009), as a measure
of the acute stress response. This study design enabled us to
determine the effects of CRF and AST on stressors that produce
predictable increases and decreases in REM.
Methods
Subjects
Male BALB/cJ mice (n = 18) were obtained from Jackson
Laboratory, Bar Harbor, Maine. The mice weighed 20–25 g at
arrival. Animals were individually housed with food and water
available ad libitum. The mouse colony room was kept on a 12:12
light-dark cycle and ambient temperature was maintained at
24 ± 1.5◦C. Throughout the experimental procedures, measures
were taken to minimize unnecessary pain and discomfort of the
animals.
Surgery
All mice were implanted intraperitoneally with telemetry
transmitters (DataSciences ETA 10-F20) for recording EEG,
body temperature and activity as previously described (Tang and
Sanford, 2002). EEG leads from the transmitter body were led
subcutaneously to the head, and the free ends were placed into
holes drilled in the dorsal skull to allow recording cortical EEG.
In the same surgery, the mice were stereotaxically implanted with
a cannula to allow ICV microinjections. A hole was drilled in the
skull 1.00mm lateral and 0.5mm posterior to Bregma and the tip
of a 26-gauge stainless steel infusion cannula was placed 2.00mm
below the skull surface into the right ventricle. The cannula was
secured to the skull with dental cement and a stylus was inserted
to maintain patency. All surgeries were performed under aseptic
conditions and with the mice under isoflurane (as inhalant: 5%
induction; 1–2% maintenance) anesthesia. Ibuprofen (30mg/kg,
orally) was continuously available in each animal’s drinking
water for 24–48 h preoperatively and for a minimum of
72 h postoperatively to alleviate potential postoperative pain.
Antibiotics (gentamicin 5–8mg/kg and Procaine penicillin
100,000 IU/kg) were given subcutaneously preoperatively to
prevent infection. Dexamethazone [0.4mg (0.2ml total dosage)]
was administered subcutaneously preoperatively to reduce brain
swelling. All procedures were conducted in accordance with the
National Institutes of Health Guide for the Care and Use of
Experimental Animals and were approved by Eastern Virginia
Medical School’s Animal Care and Use Committee.
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Baseline and Control Recordings
The mice were housed and studied in the same room. Cages and
bedding were changed 2 days prior to recording onset for each
phase of the experiment and then not disturbed until that phase
was complete.
The mice were allowed a post-surgery recovery period of 19–
20 days prior to beginning the experiment. Undisturbed baseline
(Base) recordings were then obtained for 2 days. Afterwards,
the mice were habituated to two daily sessions of the handling
procedures needed for administering microinjections. Sleep also
was recorded following a 30min exposure to a novel chamber [an
enclosure of approximately the same dimensions as the shock
chambers (20 × 40 × 30 cm)] with an open top and walls and
floor constructed of clear Plexiglas™. This recording session
controlled for handling and exposure to a non-cage environment
and was used as a handling control (HC) for comparisons across
treatment conditions.
Signaled Escapable and Inescapable Shock
(SES/SIS) Training Procedures
The mice were randomly assigned to either SES (n = 9) or SIS
(n = 9) conditions. Training was conducted in a shuttlebox
(Model E10-15SC, Coulbourn Instruments, Whitehall, PA)
consisting of two chambers divided by a guillotine door.
Opening and closing of the guillotine door, as well as the
tone (90 dB, 2 kHz, 10 s maximum) and footshock (0.5mA;
5.0 s maximum) administration were controlled by Coulbourn
Graphic State (GS) software (version 2.1). Electric footshock was
produced via Coulbourn Precision Regulated Animal Shockers
and administered via grid floors of a shuttlebox. Training started
between the third and fourth hour after lights on. The entire
training procedure was of approximately 30min duration. For
the first 5min (pre-shock period), the mice were allowed to freely
explore the shuttlebox followed by presentation of 20 shocks.
The tone was presented 5 s prior to the footshock to signal its
onset.When footshock was administered, the SESmice were then
able to move through the door to the unoccupied chamber. This
movement caused interruption of photo-beam sensors which was
detected by GS software and terminated shock presentation and
tone. If the animal did not move to the unoccupied chamber,
the shock and tone co-terminated after 5 s. Footshock for SES
mice was escapable, but not avoidable, for movement prior to
footshock onset did not prevent shock presentation. SES and
SIS mice were simultaneously trained as yoked pairs such that
SIS mice received identical amounts of shock as a mouse in the
SES group, but could not alter shock duration by their actions.
After the final shock, the animals remained undisturbed in the
shuttlebox for 5 additional min (post-shock period) and then
were returned to their home cages.
The mice received 2 days of 20 (1.0min intervals) tone-shock
pairings without drug administration to stabilize responses. On
four subsequent days, the mice were administered saline (SAL),
CRF or AST prior to SES or SIS. The experiment was pseudo-
counterbalanced in that the series of CRF microinjections were
completed before starting the series of AST microinjections.
SAL was administered such that approximately half the
mice received SAL on each of the four training days.
Each shock presentation day with injection was separated by
1 week.
Drugs and Microinjections
After recovery from surgery, ICV location of the cannula was
verified with administration of angiotensin (200 ng in 0.2µl ICV)
and observation for drinking. A positive angiotensin-induced
drinking response was shown by all mice included in the study.
CRF and AST [cyclo(33)[D-Phe12,N1e21,38,Glu30,Lys33]
h/rCRF(12-41)] were obtained in powder form from Sigma-
Aldrich (St. Louis, MO) and were diluted to the desired
concentrations in pyrogen-free SAL. Concentrations [CRF 0.4µg
(0.42mM); AST: 1.0µg (1.4mM)] used in this experiment were
based on dosages used in previous studies (Sanford et al., 2008;
Yang et al., 2009).
For microinjections, an injection cannula (33 ga.), which
projected 1.0mm beyond the tip of the implanted guide cannula,
was inserted and secured in place. The injection cannula was
connected to lengths of polyethylene tubing that in turn were
connected to a 5.0µl Hamilton syringe. The injection cannula
and tubing had been pre-filled with the solution to be injected.
The solutions in a volume of 0.2µl were slowly infused over
1min and administered 15min prior to beginning shock training.
Sleep Recording and Determination of Sleep
State
Sleep and wakefulness of the animals were monitored in the
colony room. Recording started at the fifth hour after lights on.
The transmitters for the mice were activated with a magnetic
switch, and their home cages were placed on a telemetry receiver
(Model RPC-1, Data Sciences International). When the animals
were not on study, the transmitters were inactivated. Signals from
the transmitter were detected by the receiver, and were processed
and saved by Data Sciences International software for subsequent
visual scoring. Sleep and wakefulness were determined by a
trained observer in 10-s epochs using SleepWave software
(Biosoft Studio). Each epoch was scored either as NREM, REM,
active wakefulness (AW), or quiet wakefulness (QW), based on
EEG and gross whole body activity as previously described (Tang
and Sanford, 2002). Twenty hours uninterrupted sleep recordings
were collected for Base and after each experimental session.
Data Analyses
Data were analyzed using Sigmaplot 12 software (Systat
Software, Inc. San Jose, CA). The data were primarily analyzed
with two-way mixed factorial ANOVA procedures (Group X
Treatment Day with repeated measures on Treatment Day.
When appropriate, post-hoc comparisons among means were
conducted using Holm-Sidak tests. Differences were considered
significant at p < 0.05.
Results
Amounts of REM, NREM and total sleep did not differ across the
two SAL recording days. We therefore collapsed data for these 2
days and made comparisons across Base, HC, SAL, CRF, or AST
prior to shock training. Analyses were conducted on the total 20 h
recordings and on the 8 h light and 12 h dark periods.
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Effects of CRF and AST on Stress-induced
Alterations in REM
Total REM and REM Percentage
The ANOVA for total 20 h REM amounts revealed a significant
Treatment Day effect [F(4, 64) = 2.85, p < 0.03] and a Group
X Treatment Day interaction [F(4, 64) = 3.55, p < 0.02]. Post-
hoc comparisons across Treatment Days revealed a significant
difference in REM between the SES and SIS groups only on
the SAL day (Figure 1A). Amounts of REM during Base, and
on the HC, CRF and AST recording days did not significantly
differ between groups. Thus, administration of either CRF or
AST reduced or eliminated the differences normally seen between
mice trained with SES and SIS, i.e., CRF reduced REM in the
SES mice to levels seen in the SIS mice and AST attenuated
the reduction in REM in the SIS mice to levels that were not
significantly different from those in the SES mice. The difference
between groups on the SAL day was found primarily during the
dark period which was also characterized by a significant Group
X Treatment Day interaction [F(4, 64) = 2.98, p < 0.03] and
similar findings across Treatment Days (Table 1). The analysis
for light period total REM found a significant Treatment Day
effect [F(4, 64) = 5.67, p < 0.01]. REM was reduced on the CRF
Treatment Day compared to Base, HC, and AST (Table 1), but
there were no significant differences between groups.
A similar Main Effect for Treatment Day [F(4, 64) = 4.92,
p < 0.01] and a Group X Treatment Day interaction [F(4, 64) =
3.92, p < 0.01] were found for the analyses of total 20 h REM
percentage (of total sleep time) and a significant interaction for
dark period REM percentage [F(4, 64) = 3.45, p < 0.02].
Differences between SES and SIS mice also were found only on
the SAL Treatment Days (Figure 1B, Table 1). As with total REM
amounts, the analysis for the light period did reveal any Group
differences, though there was a significant Treatment Day effect
[F(4, 64) = 10.22, p < 0.001]. REM percentage was reduced on
the CRF Treatment Day compared to Base, HC, SAL, and AST
(Table 1).
Number of REM Episodes and REM Episode Duration
There were no significant differences in number of REM
episodes (Figure 1C) or REM episode duration (Figure 1D) in
the analyses of the 20 h recording period. However, there was a
significant Treatment Day effect for number of REM episodes
during the light period [F(4, 64) = 4.41, p < 0.01] and the
post-hoc analysis found significantly reduced REM episodes on
the CRF day compared to the Base day (Table 1). There also
was a significant Treatment Day effect for REM episode duration
during the light period [F(4, 64) = 3.71, p < 0.01] and
the post-hoc analysis found significantly reduced REM episode
duration on the CRF day compared to HC (Table 1). No other
comparisons were significant.
Effects of CRF and AST on Stress-induced
Alterations in NREM, Total Sleep Time, and
Wakefulness
NREM and Total Sleep Time
Total 20 h TST (Figure 2A) and NREM amounts (Figure 2B)
did not vary across condition or group. However, there was
a difference across Treatment Days for light period NREM
[F(4, 64) = 3.44, p < 0.02] and TST [F(4, 64) = 4.15, p < 0.01].
Light period NREM was reduced on the CRF day compared to
the HC day and light period TST was reduced on the CRF day
compared to the HC and AST Treatment Days (Table 2). No
other comparisons were significant.
The analysis of NREM episodes for the 20 h recording period
(Figure 2C) revealed significant effects for Group [F(1, 16) =
10.305, p < 0.01] and Treatment Day [F(4, 64) = 8.483, p <
0.001]. This effect was primarily due to the increased number of
NREM episodes in the SIS mice compared to the SES mice on the
SAL andCRF treatment days compared to Base andHC. Virtually
identical results were found for the analyses of the light [Group
(F(1, 16) = 7.949, p < 0.02) and Treatment Day [F(4, 64) = 5.504,
p < 0.001)] and dark [Group (F(1, 16) = 4.973, p < 0.02] and
Treatment Day [F(4, 64) = 6.567, p < 0.001)] periods (Table 2).
There was a main effect for Treatment Day in the analysis
of the NREM episode duration (Figure 2D) for the total 20 h
recording period [F(4, 64) = 7.669, p < 0.001). NREM episode
duration was reduced on the SAL and CRF treatment days
compared to Base and to the HC Treatment Day. There also
was a significant Treatment Day effect during the light period
[F(4, 64) = 5.588, p < 0.001]; however, the reductions in NREM
episode duration for the SAL and CRF treatment days were
significantly reduced only compared to the HC treatment day
(Table 2).
The analysis of NREM episode duration for the dark period
revealed a significant effect for Treatment Day [F(4, 64) = 6.610,
p < 0.011] and a significant Group X Treatment Day [F(4, 64) =
2.569, p < 0.05]. The duration of dark period NREM episodes
were significantly reduced in the SIS mice than in the SES mice
on the SAL and CRF treatment days (Table 2).
Active Waking and Quiet Waking
Total 20 h amounts of active waking did not significantly differ
across groups or conditions (Figure 3A). By comparison, the
analysis of quiet waking revealed a significant Treatment Day
effect [F(4, 64) = 5.13, p < 0.01]. Quiet waking was greater on
the CRF day than on the HC or AST treatment days (Figure 3B).
There also was significant effect for Quiet waking in the light
period [F(4, 64) = 9.274, p < 0.001]. Light period quiet waking
was significantly greater during Base and on the SAL and CRF
treatment days than on the HC or AST treatment days (Table 2).
Effects of CRF and AST on Stress-induced
Alterations in Core Body Temperature
We examined changes in core body temperature hourly across
the first 4 h of recording to assess potential differences in SIH
produced by SES (Figure 4A) and SIS (Figure 4B) and the effects
of CRF and AST. The ANOVAs revealed a main effect for
Treatment Day for h 1 [F(4, 64) = 9.083, p < 0.001]; h 2
[F(4, 64) = 11.721, p < 0.001] and h 3 [F(4, 64) = 3.013,
p < 0.03]. In h 1, compared to Base, core body temperature
was significantly increased for HC, SAL, CRF, and AST. In h 2,
temperature in the HC treatment did not differ significantly from
that in Base, but remained elevated in SAL, CRF, and AST. There
also was a Group effect in h 2 [F(1, 16) = 4.505, p < 0.05] and
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FIGURE 1 | REM sleep plotted as 20h totals for baseline (Base),
handling control (HC) and for days on which the mice received ICV
injections of saline (SAL), corticotropin releasing factor (CRF) or
astressin (AST) prior to signaled, escapable shock (SES) or to
signaled, inescapable shock (SIS) training. (A) Total REM; (B) REM %
(total REM/total sleep time × 100%); (C) REM episodes; (D) average REM
episode duration. Comparisons of SES (n = 9) and SIS (n = 9): *p < 0.05.
Values are means ± SEM.
temperature was greater in the SES mice (36.83◦C) than in the
SIS mice (36.33◦C). In h 3, temperature remained significantly
higher in the CRF and AST treatment condition compared to
Base whereas the difference for SAL did not reach significance
(p = 0.07). There were no significant differences between SES
and SIS, and by h 4, temperature had returned to Base levels in all
conditions.
Discussion
The present results support previous studies (Sanford et al.,
2010; Yang et al., 2011a,b) demonstrating that signaled and
non-signaled controllable and uncontrollable stress are followed
by directionally different alterations in REM in the post-stress
period even though the acute stress response (as indicated by
SIH) is similar. The results also indicate that centrally acting
CRF is a significant factor in the reduction in REM that follows
uncontrollable stress. This conclusion is supported by findings
that differences in REM between SES and SIS trained mice
are reduced by ICV administration of CRF and AST, with
CRF resulting in reduced REM in both groups and with AST
attenuating the reduction in REM in the SIS group. SIS, but not
SES, also produced significant changes in NREM architecture,
but not total amount, which were ameliorated by antagonizing
CRF. The increases in the number of NREM episodes and
decreases in NREM episode duration after SIS suggests more
fragmented sleep even though the amount of sleep did not
change. Thus, our results indicate a strong role for CRF in
mediating stress-induced reductions in REM and a likely role for
CRF in disrupting sleep continuity after certain types of stressors.
Despite significant differences in REM, SIH was similar for SIS
and SES treatments with and without co-administration of CRF
or AST. These data suggest that central CRF may play a minimal
role in modulating stress-induced alterations in temperature in
this model or that sleep may be more sensitive to perturbations
of the central CRF system than are peripheral indices of the stress
response.
Stressor Controllability and Predictability and
Sleep
Whether an animal perceives stressors as controllable and/or
predictable appears to be an important factor in the effects of
stress (Abbott et al., 1984; Adell et al., 1988). Both controllability
and predictability can significantly influence post-stress sleep,
and there appears to be the potential for interactions between
the type of stress-related information available to the animal,
its processing of that information, and the subsequent effects
on sleep. In previous work, we demonstrated that auditory cues
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TABLE 1 | Selected REM sleep parameters for the 8h light period and 12h dark period during baseline (Base), handling control (HC), and for days on
which the mice received ICV injections of saline (Sal), corticotropin releasing factor (CRF) or astressin (AST) prior to training with signaled, escapable
shock (SES) or signaled, inescapable shock (SIS).
Base HC Sal CRF AST
LIGHT PERIOD
REM total SES 13.4± 2.4 15.5± 2.5 12.6± 2.0 5.7± 1.6+#∧ 15.2± 4.9
SIS 16.4± 2.6 16.2± 2.1 9.1± 1.7 9.0± 2.6+#∧ 11.7± 2.4
REM % SES 6.1± 0.8 5.7± 0.7 5.6± 0.8 2.9± 0.7+#¤∧ 5.7± 1.4
SIS 6.6± 0.9 6.11± 0.6 3.5± 0.6 2.6± 0.5+#¤∧ 4.3± 0.8
REM episodes SES 11.5± 2.9 10.5± 1.4 9.8± 1.5 4.9± 1.1# 10.6± 2.8
SIS 12.5± 2.1 11.9± 2.1 7.8± 1.3 6.8± 1.5# 9.8± 2.2
REM duration SES 0.7± 0.07 0.72± 0.07 0.65± 0.07 0.46± 0.10+# 0.59± 0.06
SIS 0.67± 0.05 0.77± 0.07 0.58± 0.05 0.58± 0.06+# 0.64± 0.13
DARK PERIOD
REM total SES 27.8± 4.8 24.0± 3.6 36.4± 3.1* 26.4± 4.0 30.9± 3.9
SIS 28.6± 3.4 31.2± 3.3 24.6± 2.0 26.5± 2.9 29.3± 4.0
REM % SES 8.3± 1.1 8.0± 1.0 11.1± 0.9* 7.6± 0.9 10.1± 0.9
SIS 9.5± 0.9 9.6± 0.8 7.7± 0.8 6.6± 1.4 8.9± 1.2
REM episodes SES 15.3± 3.2 10.1± 1.8 13.2± 1.2 11.0± 1.6 11.0± 1.6
SIS 11.1± 1.1 12.3± 2.0 11.4± 1.2 11.1± 1.5 11.2± 1.2
REM duration SES 0.87± 0.1 0.78± 0.06 0.90± 0.06 0.70± 0.04 0.83± 0.06
SIS 0.82± 0.08 0.83± 0.07 0.76± 0.07 0.79± 0.05 0.78± 0.06
Comparisons between SES (n = 9) and SIS (n = 9): *p < 0.05; Comparisons to Base: +p < 0.05; Comparisons to HC: #p < 0.05; Comparisons to Sal: ¤p < 0.05; Comparisons to
AST: ∧p < 0.05. Values are means ± SEM. Total REM and REM Duration are reported in minutes; REM% was calculated as total REM/total sleep time × 100%, and REM Episodes are
reported as number of episodes.
that predict shock can modify its effects on sleep and, contrary
to contexts associated with non-signaled escapable footshock,
do not produce conditioned increases in REM (Yang et al.,
2011a). Learning the appropriate escape response (control) is also
necessary for increases in REM (Machida et al., 2013).
The state of the animal at the time of stress also appears to be
important. The brief manual restraint necessary for conducting
microinjections is itself a stressor that can impact the animals and
significantly alter subsequent sleep (Tang et al., 2007). It can also
influence the effects of other stressors on sleep (Tang et al., 2007).
For example, in rats, 5min of manual restraint administered
prior to 20 inescapable footshocks prevented the decrease in light
period REM normally observed when inescapable footshock is
presented without prior restraint. In a previous study reporting
on the effects of SIS and SES without prior microinjections, we
found an increase in NREM after shock training in SIS mice
compared to SES mice (Yang et al., 2011a) that we did not see
in the present study. This difference may have been due to the
handling needed to complete the microinjections, as all other
conditions were virtually the same across studies. Thus, our
results should be interpreted in the context of the effects of CRF
and AST on two interacting stressors, brief restraint and SES or
SIS, as well as the complex emotions and memories and potential
learning associated with the two conditions.
CRF and the Regulation of Sleep and Arousal
Several lines of existing data indicate that CRF is a significant
regulator of stress-induced alterations in sleep and arousal;
however, its actual role remains to be clarified. Studies
administering antagonists prior to or during the presentation
of stressors (González and Valatx, 1997) or sleep deprivation
(González and Valatx, 1998; Kimura et al., 2010) have led to the
conclusion that CRF can promote REM. Interestingly, there also
is evidence that systemic administration of some CRF antagonists
can inhibit spontaneous REM in adult (Ahnaou et al., 2012)
and neonatal (Liu et al., 2010) rats, which can be considered
supportive of this conclusion. However, studies that administered
CRF prior to stress (Yang et al., 2009, 2011b) or during the
recovery period after sleep deprivation (Schüssler et al., 2006)
indicate that CRF can be inhibitory to REM. Under non-stress
conditions, we also found that ICV administration of AST
decreased wakefulness and increased REM in stress-responsive
BALB/cJ mice, but not in less-responsive C57BL/6Jmice, whereas
CRF decreased REM in both strains (Sanford et al., 2008). Both
of these studies can be considered consistent with the hypothesis
that CRF has a suppressing effect on REM.
Resolving the discrepancies regarding the role of CRF in
mediating the effects of stress on REM will likely require
considering the relationship between the time course of the CRF
stress response and that of stress-induced alterations in sleep and
arousal. Many indices of stress including corticosterone (Veening
et al., 2004; van Bogaert et al., 2006), SIH (Veening et al., 2004;
van Bogaert et al., 2006), and activation of the hypothalamic
paraventricular nucleus and other stress reactive regions in the
brain (Grahn et al., 1999; Coco and Weiss, 2005; Liu et al., 2009)
return to pre-stress levels relatively shortly after termination of
an acute stressor. By comparison, alterations in sleep can occur
several hours into the post-stress period. Studies administering
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FIGURE 2 | Total sleep and amounts of NREM sleep plotted as 20h
totals for baseline (Base), handling control (HC) and for days on
which the mice received ICV injections of saline (SAL), corticotropin
releasing factor (CRF) or astressin (AST) prior to signaled, escapable
shock (SES) or to signaled, inescapable shock (SIS) training. (A) Total
sleep; (B) Total NREM sleep; (C) NREM episodes; (D) average NREM
episode duration. Comparisons of SES (n = 9) and SIS (n = 9): *p < 0.05.
Values are means ± SEM.
an antagonist prior to presenting the stressor simply may have
prevented or attenuated the initial CRF response which then
altered the subsequent post-stress increase in REM that is
seen with many stressors. Whether CRF is acting centrally or
peripherally may also have consequences for its potential effects
on REM in stress or non-stress conditions. This is suggested
by findings that elevations of corticosterone after CRF is given
ICV appear to be able to reduce REM even in CRF receptor 1
knockout mice (Romanowski et al., 2010).
The complexity of trying to assess the role of CRF inmediating
sleep is also exemplified in work in humans. Four intravenous
injections of human CRF at hourly intervals increased cortisol
and reduced both REM and NREM in young healthy male
volunteers (Holsboer et al., 1988). By comparison, hourly
intravenous administration of cortisol decreased REM and
increased NREM and plasma cortisol concentrations (Born et al.,
1989; Friess et al., 1994). Together, these studies suggest that
the decrease in REM after systemic CRF is mediated by cortisol,
whereas the decrease in NREM may be a direct effect of CRF.
CRF also appears to contribute to disinhibition of REM sleep
and impaired NREM in depression, which is thought to be a
stress related disorder. For example, administration of a CRF
antagonist to patients with depression decreased REM density
and awakenings and increased NREM (Held et al., 2004). Thus,
the effects of CRF also may vary with route of administration,
potentially with species, and across situations with altered neural
functioning.
CRF and Stress-induced Hyperthermia
Stress-induced increases in core body temperature can begin
within 10 s of the onset of stress induction (Clement et al., 1989;
Krarup et al., 1999) and can be asmuch as 2◦C in rats andmice for
a variety of stressors including handling stress, exposure to novel
environments, and restraint (Briese and De Quijada, 1970; Singer
et al., 1986; Clement et al., 1989; Zethof et al., 1994). Anxiolytic
drugs can decrease SIH (Vinckers et al., 2009). By comparison,
some anxiogenic drugs have minimal effects on SIH possibly due
to a maximum limit to the amount temperature may increase
(Vinckers et al., 2009) whereas others may reduce or prevent SIH
responses (Houtepen et al., 2011).
All of the stress conditions that we examined produced
increases in average body temperature relative to time matched
Base though there were differences in the time course of the
response. Notably, the HC condition, putatively a milder stressor,
returned to Base levels more rapidly whereas the conditions
involving foot shock (both SES and SIS) had more persisting
increases, regardless of whether the mice had received SAL, AST,
or CRF.
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TABLE 2 | Total sleep, NREM and wake parameters for the 8h light period and 12h dark period during baseline (Base), handling control (HC), and for days
on which the mice received ICV injections of saline (Sal), corticotropin releasing factor (CRF) or astressin (AST) prior to training with signaled, escapable
shock (SES) or signaled, inescapable shock (SIS).
Base HC Sal CRF AST
LIGHT PERIOD
Total sleep SES 211.4±19.7 269.3±21.0 231.5± 19.2 182.8± 14.2#∧ 239.7± 24.1
SIS 250.8±20.6 259.9±16.6 254.3± 10.9 241.1± 7.6#∧ 270± 16.9
NREM total SES 198±18.0 253.8±19.7 218.2± 18.7 177.1± 13.1# 224.6± 20.8
SIS 234.4±19.3 243.7±15.0 245.2± 10.0 234.9± 7.5# 258.3± 16.3
NREM episodes SES 116.9±16.3 1.22±11.9 159.4± 14.8* 133.6± 18.4* 140.6± 11.2
SIS 150.9±13.8 143.6±10.8 192.9± 13.4 198.7± 13.0 168.7± 12.8
NREM duration SES 1.70±0.18 1.86±0.22 1.26± 0.15# 1.44± 0.24# 1.56± 0.22
SIS 1.49±0.19 1.53±0.16 1.10± 0.06# 1.12± 0.10# 1.36± 0.12
Active wake SES 132.8±20.0 96.3±17.0 111.6± 18.9 134.7± 21.2 130.5± 22.0
SIS 89.1±11.7 99.9±11.7 85.8± 11.2 91.2± 6.5 89.9± 14.1
Quiet wake SES 135.8±9.7#∧ 114.5±9.5 136.9± 12.8#∧ 162.6± 13.2#∧ 109.7± 7.1
SIS 140.1±14.6#∧ 120.3±8.3 139.9± 4.7#∧ 147.7± 6.4#∧ 120.1± 7.9
DARK PERIOD
Total sleep SES 323.8±26.9 298.7±20.5 328.6± 18.0 339.6± 26.0 299.6± 25.4
SIS 299.8±21.2 326.2±15.9 323± 9.5 344.9± 21.2 328.3± 16.6
NREM total SES 296±23.7 274.7±18.7 292.2± 17.0 313.2± 23.8 268.7± 22.4
SIS 271.2±19.0 295±14.8 298.5± 10.5 320.7± 17.4 298.9± 15.1
NREM episodes SES 139.1±9.9 166.8±15.4 179.5± 24.4* 179.3± 12.8* 164.9± 18.2
SIS 161.3±15.4 162.3±17.3 230.3± 12.2 245.8± 19.4 188.3± 15.0
NREM duration SES 1.97±0.31 1.23±0.06 1.36± 0.16 1.36± 0.23 1.02± 0.18
SIS 1.75±0.22 1.33±0.11 1.12± 0.13 1.23± 0.12 1.14± 0.22
Active wake SES 197.8±13.1 209.1±25.9 203.2± 28.1 168.8± 20.1 233.2± 32.7
SIS 212.3±29.4 195.7±16.9 182.3± 11.2 156.7± 13.8 189.1± 18.9
Quiet wake SES 198.4±17.3 212.2±14.1 188.2± 13.7 211.6± 19.2 187.2± 17.9
SIS 207.9±16.7 198.1±11.0 214.6± 7.8 218.4± 13.1 202.7± 11.5
Comparisons between SES (n = 9) and SIS (n = 9): *p < 0.05. Comparisons to Base: +p < 0.05. Comparisons to HC: #p < 0.05. Comparisons to AST: ∧p < 0.01. Values are means ±
SEM. Total Sleep, NREM Total, NREM Duration, Active Wake, and Quiet Wake are reported in minutes. NREM Episodes are reported as number of episodes.
FIGURE 3 | Total amounts of active waking (A) and quiet waking
(B) plotted as 20h totals for baseline (Base), handling control
(HC) and for days on which the mice received ICV injections of
saline (SAL), corticotropin releasing factor (CRF), or astressin
(AST) prior to signaled, escapable shock (SES, n = 9) or to
signaled, inescapable shock (SIS, n = 9) training. Comparisons of
CRF to HC: ++, p < 0.01. Comparisons of CRF to AST: ∧∧p < 0.01.
Values are means ± SEM.
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FIGURE 4 | Average core body temperature plotted hourly for the
first 4 h of the 20h recording period for mice trained with
signaled, escapable shock (SES, A) or signaled, inescapable
shock (SIS, B) training. Average temperature is shown for baseline
(Base), handling control (HC), and for ICV microinjections of saline
(SAL), corticotropin releasing factor (CRF), and astressin (AST) prior to
SES (n = 9) or SIS (n = 9). Comparisons to Base: *p < 0.05. Values are
means ± SEM.
As we reported before for training with ES alone (Yang
et al., 2011b), AST did not produce a significant attenuation
of SIH for either SES or SIS trained mice. However, other
studies have reported that CRF antagonists attenuate
SIH. The CRF receptor 1 antagonists antalarmin and
SSR125543A [4-(2-chloro-4-methoxy-5-methylphenyl]-N-[(1S)-
2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-
(2-propynyl)-1,3-thiazol-2-aminehydrochloride) administered
orally or intraperitoneally reduce SIH in rats subjected to
isolation stress (Griebel et al., 2002). ICV administration
of the broad CRF antagonist αHelCRF in rats also reduced
body temperature after exposure to a cage change stressor
(Morimoto et al., 1993; Nakamori et al., 1993). Interestingly,
central administration of CRF in rats produces an increase in
body temperature (Heinrichs et al., 2001; Figueiredo et al., 2010)
that is attenuated by AST and antalarmin (Figueiredo et al.,
2010).
The reason for the differences compared to our results is not
clear, but both isolation and cage change likely are less intense
stressors than the footshock paradigm used in our studies. They
also likely involve only psychological stress whereas footshock
involves both psychological and strong physiological stress which
would activate additional neural pathways. Furthermore, though
in vitro assays indicate that AST is more potent for both CRF1
and CRF2 receptors than is αHelCRF (Hauger et al., 2006),
in vivo studies in rats suggest that AST may be less potent in
preventing some CRF- and stress-induced and anxiety-related
behaviors including CRF-induced locomotor activity (Spina
et al., 2000). It is also possible that a higher dosage of AST
than we used (1.0µg) may be effective in reducing SIH. For
example, a 5.0µg, but not a 1.0µg, dosage of AST blocked
the reduction in the number of entries into the open arms of
an elevated plus maze produced by central administration of
0.5µg CRF (Spina et al., 2000). Strain or species differences
in the central CRF system could also be involved. BALB/cJ
mice, the strain used in this study, have differences in their
CRF system (Blank et al., 2003) and reactivity to CRF and
CRF antagonists compared to C57BL/6J mice (Sanford et al.,
2008), thereby suggesting differences in the regulation of sleep
by CRF.
CRF and the Functional Significance of
Post-stress Sleep
SIH responses have a time course that parallels that of
hypothalamic-pituitary-adrenal (HPA) axis activation (Veening
et al., 2004; van Bogaert et al., 2006) and both SIH and
corticosterone (Shors et al., 1989) are similarly enhanced by
ES and IS which are followed by distinctly different alterations
in sleep. Fear, as indicated by behavioral freezing, also is very
similar in response to contextual reminders of SES and SIS
(Machida et al., 2013) or ES and IS alone (Yang et al., 2011a).
This suggests that the mere presence of a peripheral stress
response and fearful behavior do not dictate, or even predict,
the types of alterations in sleep that occur after acute stress.
Instead, post-stress sleep appears to be a function of the context
in which the stressor was encountered and the emotional and
learning processes that were engaged as the animal evaluated
and reacted to the situation. In line with the effects of waking
experiences on sleep, various lines of evidence suggest that,
in turn, sleep plays a significant role in adaptive responding
to stress. For instance, sleep disturbances both before (Bryant
et al., 2010) and after (Lavie, 2001) significant or traumatic
events have been linked to the development of stress-related
pathology.
The increases in REM that occur following controllable stress
(Sanford et al., 2010) and following fear extinction (Wellman
et al., 2008), and the decreases in REM that can occur without
recovery following uncontrollable stress (Liu et al., 2003; Sanford
et al., 2003c) and associated with learned helplessness (Adrien
et al., 1991) suggest that post-stress REM may play a role in
adaptive responses to stress. This is also consistent with findings
in posttraumatic stress disorder (PTSD) patients that found, in
sleep recordings soon after trauma, a more fragmented pattern
of REM characterized by shorter average duration REM episodes
before shifting stage or awakening in PTSD patients compared to
patients without PTSD and a non-traumatized comparison group
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(Mellman et al., 2002, 2007). There were also a greater number
of REM episodes in the PTSD patients than in patients that
experienced trauma without developing PTSD. These differences
led to the suggestion that intact REM aids in the processing
of memory for trauma (Mellman et al., 2002, 2007). Similar
hypotheses emphasizing a positive role for REM in mediating
the effects of stress have been put forth including suggestions
that REM plays an important role in consolidating memories
for aversive events and in “decoupling” those memories from
their emotional charge (Nishida et al., 2009; Walker, 2009) and
that it serves to weaken unwanted memory traces in the cortex
(Crick andMitchison, 1983). Experimental paradigms employing
controllable and uncontrollable stressors that produce clear
distinctions in post-stress sleep should be useful for determining
the role that sleep may have in orchestrating neurobiological
changes that promote adaptive behaviors and the role that
impaired sleep may play in stress-induced pathologies.
The current results suggest that centrally acting CRF is a
significant regulator of post-stress sleep. It also has been linked
to stress-related psychopathology. Elevated levels of CRF have
been found in the cerebrospinal fluid (Bremner et al., 1997; Baker
et al., 1999; Sautter et al., 2003) and plasma (de Kloet et al.,
2007) of PTSD patients and elevated CRF coupled with either
enhanced negative feedback or downregulated CRF receptors
has been hypothesized to play a role in the reduced delta sleep
found in patients with PTSD (Neylan et al., 2006). Stress also
can be a significant factor in insomnia (Healey et al., 1981;
Basta et al., 2007) which is associated with higher activity in the
HPA axis and considered to be a disorder of hyperarousal in
the central nervous system (Bonnet and Arand, 1997; Vgontzas
et al., 2001; Basta et al., 2007). Increased CRF activity figures
prominently in hypotheses regarding the pathogenesis of primary
insomnia (Richardson and Roth, 2001). Thus, CRF may be
a significant mediator of the stress and arousal/sleep systems
and their interactions in regulating the outcomes of stressful
experiences. This is also suggested by our recent findings that
antagonizing CRF in the basolateral nucleus of the amygdala
(BLA) prior to training with inescapable shock blocked the
reductions in REM that normally occur (Wellman et al., 2013). It
also blocked subsequent conditioned reductions in REM without
reducing freezing, suggesting that fear memory had been altered,
but not blocked. By comparison, inactivation of BLA with the
GABAergic agonist, muscimol, blocked the reduction in REM,
and reduced freezing (Wellman et al., 2014), suggesting that
CRF was working in a region that mediates the memory linkage
between fearful behaviors and sleep.
A Note on Experimental Design
We chose to complete the microinjections of CRF before we
conducted studies with AST. This was based on the concern that
antagonizing CRF early in the series might alter subsequent stress
responses, or the impact of stress on sleep. For that reason, we
conducted SAL controls for both CRF and AST to be able to
determine whether there were potential carryover effects across
the experiment. Based on these controls, the effects of SES and
SIS were consistent across treatment days, with the exception of
the relative effects of CRF and AST on stress-induced alterations
in sleep.
Conclusion
Post-stress sleep appears to be determined by the types of
information available in the stressful context, the animal’s
processing of that information, and the emotional responses that
are induced. Post-stress sleep, in particular REM, also appears
to play a role in mediating the positive or negative outcomes of
stress, and behavioral experiences during wakefulness likely set in
motion the underlying neurobiological processes that guide and
enable sleep to mediate the effects of stress. The current results
demonstrate that centrally acting CRF is a major regulator of
post-stress alterations in sleep that may occur independently of
the induction of the peripheral stress response. Work focused
on understanding the role that central CRF has in regulating
interactions between the stress and arousal/sleep systems should
provide insight into the neural processes that are associated with
adaptive and non-adaptive responding to stress.
Acknowledgments
This work was supported by NIH research grants MH61716 and
MH64827.
References
Abbott, B. B., Schoen, L. S., and Badia, P. (1984). Predictable and unpredictable
shock: behavioral measures of aversion and physiological measures of stress.
Psychol. Bull. 96, 45–71. doi: 10.1037/0033-2909.96.1.45
Adell, A., Trullas, R., and Gelpi, E. (1988). Time course of changes in serotonin and
noradrenaline in rat brain after predictable or unpredictable shock. Brain Res.
459, 54–59. doi: 10.1016/0006-8993(88)90285-5
Adrien, J., Dugovic, C., and Martin, P. (1991). Sleep-wakefulness patterns in the
helpless rat. Physiol. Behav. 49, 257–262. doi: 10.1016/0031-9384(91)90041-L
Ahnaou, A., Steckler, T., Heylen, A., Kennis, L., Nakazato, A., Chaki, S., et al.
(2012). R278995/CRA0450, a corticotropin-releasing factor (CRF(1)) receptor
antagonist modulates REM sleep measures in rats: implication for therapeutic
indication. Eur. J. Pharmacol. 680, 63–68. doi: 10.1016/j.ejphar.2012.01.023
Aloisi, A. M., Bianchi, M., Lupo, C., Sacerdote, P., and Farabollini, F. (1999).
Neuroendocrine and behavioral effects of CRH blockade and stress inmale rats.
Physiol. Behav. 66, 523–528. doi: 10.1016/S0031-9384(98)00320-5
Baker, D. G., West, S. A., Nicholson, W. E., Ekhator, N. N., Kasckow, J. W.,
Hill, K. K., et al. (1999). Serial CSF corticotropin-releasing hormone levels and
adrenocortical activity in combat veterans with posttraumatic stress disorder.
Am. J. Psychiatry 156, 585–588.
Bakshi, V. P., and Kalin, N. H. (2000). Corticotropin-releasing hormone and
animal models of anxiety: gene-environment interactions. Biol. Psychiatry 48,
1175–1198. doi: 10.1016/S0006-3223(00)01082-9
Basso, A. M., Spina, M., Rivier, J., Vale, W., and Koob, G. F. (1999).
Corticotropin-releasing factor antagonist attenuates the “anxiogenic-like”
effect in the defensive burying paradigm but not in the elevated plus-
maze following chronic cocaine in rats. Psychopharmacology 145, 21–30. doi:
10.1007/s002130051028
Basta, M., Chrousos, G. P., Vela-Bueno, A., and Vgontzas, A. N. (2007).
Chronic Insomnia and Stress System. Sleep Med. Clin. 2, 279–291. doi:
10.1016/j.jsmc.2007.04.002
Blank, T., Nijholt, I., Grammatopoulos, D. K., Randeva, H. S., Hillhouse, E.
W., and Spiess, J. (2003). Corticotropin-releasing factor receptors couple to
Frontiers in Neuroscience | www.frontiersin.org 10 July 2015 | Volume 9 | Article 258
Wellman et al. CRF, stress and sleep
multiple G-proteins to activate diverse intracellular signaling pathways in
mouse hippocampus: role in neuronal excitability and associative learning.
J. Neurosci. 23, 700–707.
Bonnet, C., Léger, L., Baubet, V., Debilly, G., and Cespuglio, R. (1997). Influence of
a 1 h immobilization stress on sleep states and corticotropin-like intermediate
lobe peptide (CLIP or ACTH18-39, Ph-ACTH18-39) brain contents in the rat.
Brain Res. 751, 54–63. doi: 10.1016/S0006-8993(96)01390-X
Bonnet, M. H., and Arand, D. L. (1997). Hyperarousal and insomnia. Sleep Med.
Rev. 1, 97–108. doi: 10.1016/S1087-0792(97)90012-5
Born, J., Späth-Schwalbe, E., Schwakenhofer, H., Kern, W., and Fehm, H. L.
(1989). Influences of corticotropin-releasing hormone, adrenocorticotropin,
and cortisol on sleep in normal man. J. Clin. Endocrinol. Metab. 68, 904–911.
doi: 10.1210/jcem-68-5-904
Bremner, J., Licinio, J., Darnell, A., Krystal, J., Owens, M., Southwick, S.,
et al. (1997). Elevated CSF corticotropin-releasing factor concentrations
in posttraumatic stress disorder. Am. J. Psychiatry 154, 624–629. doi:
10.1176/ajp.154.5.624
Briese, E., and De Quijada, M. G. (1970). Colonic temperature of rats during
handling. Acta Physiol. Lat. Am. 20, 97–102.
Bryant, R. A., Creamer, M., O’Donnell, M., Silove, D., andMcFarlane, A. C. (2010).
Sleep disturbance immediately prior to trauma predicts subsequent psychiatric
disorder. Sleep 33, 69–74.
Chang, F. C., and Opp, M. R. (1998). Blockade of corticotropin-releasing
hormone receptors reduces spontaneous waking in the rat. Am. J. Physiol. 275,
R793–R802.
Chang, F. C., and Opp, M. R. (2001). Corticotropin-releasing hormone (CRH) as a
regulator of waking. Neurosci. Biobehav. Rev. 25, 445–453. doi: 10.1016/S0149-
7634(01)00024-0
Chang, F. C., and Opp, M. R. (2002). Role of corticotropin-releasing hormone in
stressor-induced alterations of sleep in rat. Am. J. Physiol. Regul. Integr. Comp.
Physiol. 283, R400–R407. doi: 10.1152/ajpregu.00758.2001
Clement, J. G., Mills, P., and Brockway, B. (1989). Use of telemetry to record body
temperature and activity in mice. J. Pharmacol. Methods 21, 129–140.
Coco, M. L., and Weiss, J. M. (2005). Neural substrates of coping behavior in
the rat: possible importance of mesocorticolimbic dopamine system. Behav.
Neurosci. 119, 429–445. doi: 10.1037/0735-7044.119.2.429
Crick, F., and Mitchison, G. (1983). The function of dream sleep. Nature 304,
111–114. doi: 10.1038/304111a0
Deak, T., Nguyen, K. T., Ehrlich, A. L., Watkins, L. R., Spencer, R. L., Maier,
S. F., et al. (1999). The impact of the nonpeptide corticotropin-releasing
hormone antagonist antalarmin on behavioral and endocrine responses to
stress. Endocrinology 140, 79–86. doi: 10.1210/en.140.1.79
de Kloet, C. S., Vermetten, E., Geuze, E., Lentjes, E. G., Heijnen, C. J., Stalla, G.
K., et al. (2007). Elevated plasma corticotrophin-releasing hormone levels in
veterans with posttraumatic stress disorder. Prog. Brain Res. 167, 287–291. doi:
10.1016/S0079-6123(07)67025-3
Deussing, J. M., and Wurst, W. (2005). Dissecting the genetic effect of the CRH
system on anxiety and stress-related behaviour. C. R. Biol. 328, 199–212. doi:
10.1016/j.crvi.2005.01.001
Ehlers, C. L., Reed, T. K., and Henriksen, S. J. (1986). Effects of corticotropin-
releasing factor and growth hormone-releasing factor on sleep and activity in
rats. Neuroendocrinology 42, 467–474. doi: 10.1159/000124489
Figueiredo, M. J., Fabricio, A. S., Machado, R. R., Melo, M. C., Soares, D. M., and
Souza, G. E. (2010). Increase of core temperature induced by corticotropin-
releasing factor and urocortin: a comparative study. Regul. Pept. 165, 191–199.
doi: 10.1016/j.regpep.2010.07.167
Friess, E. V., Bardeleben, U., Wiedemann, K., Lauer, C. J., and Holsboer, F.
(1994). Effects of pulsatile cortisol infusion on sleep-EEG and nocturnal growth
hormone release in healthy men. J. Sleep Res. 3, 73–79. doi: 10.1111/j.1365-
2869.1994.tb00110.x
González, M. M., and Valatx, J. L. (1997). Effect of intracerebroventricular
administration of alpha-helical CRH (9-41) on the sleep/waking cycle in rats
under normal conditions or after subjection to an acute stressful stimulus.
J. Sleep Res. 6, 164–170. doi: 10.1046/j.1365-2869.1997.00042.x
González, M. M., and Valatx, J. L. (1998). Involvement of stress in the sleep
rebound mechanism induced by sleep deprivation in the rat: use of alpha-
helical CRH (9-41). Behav. Pharmacol. 9, 655–662. doi: 10.1097/00008877-
199812000-00001
Grahn, R. E., Will, M. J., Hammack, S. E., Maswood, S., McQueen, M. B., Watkins,
L. R., et al. (1999). Activation of serotonin-immunoreactive cells in the dorsal
raphe nucleus in rats exposed to an uncontrollable stressor. Brain Res. 826,
35–43. doi: 10.1016/S0006-8993(99)01208-1
Griebel, G., Simiand, J., Steinberg, R., Jung, M., Gully, D., Roger, P., et al.
(2002). 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-
fluoro-4-methylp henyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine
hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing
factor(1) receptor antagonist. II. Characterization in rodent models of
stress-related disorders. J. Pharmacol. Exp. Ther. 301, 333–345. doi:
10.1124/jpet.301.1.333
Hauger, R. L., Risbrough, V., Brauns, O., and Dautzenberg, F. M. (2006).
Corticotropin releasing factor (CRF) receptor signaling in the central nervous
system: new molecular targets. CNS Neurol. Disord. Drug Targets 5, 453–479.
doi: 10.2174/187152706777950684
Healey, E. S., Kales, A., Monroe, L. J., Bixler, E. O., Chamberlin, K., and Soldatos,
C. R. (1981). Onset of insomnia: role of life-stress events. Psychosom. Med. 43,
439–451. doi: 10.1097/00006842-198110000-00007
Heilig, M., Koob, G. F., Ekman, R., and Britton, K. T. (1994). Corticotropin-
releasing factor and neuropeptide Y: role in emotional integration. TINS 17,
80–85. doi: 10.1016/0166-2236(94)90079-5
Heinrichs, S. C., Li, D. L., and Iyengar, S. (2001). Corticotropin-releasing factor
(CRF) or CRF binding-protein ligand inhibitor administration suppresses food
intake in mice and elevates body temperature in rats. Brain Res. 900, 177–185.
doi: 10.1016/S0006-8993(01)02286-7
Heinrichs, S. C., Menzaghi, F., Merlo Pich, E., Britton, K. T., and Koob, G. F.
(1995). The role of CRF in behavioral aspects of stress. Ann. N. Y. Acad. Sci.
771, 92–104. doi: 10.1111/j.1749-6632.1995.tb44673.x
Held, K., Künzel, H., Ising, M., Schmid, D. A., Zobel, A., Murck, H., et al. (2004).
Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG
in patients with depression. J. Psychiatr. Res. 38, 129–136. doi: 10.1016/S0022-
3956(03)00076-1
Holsboer, F., von Bardeleben, U., and Steiger, A. (1988). Effects of intravenous
corticotropin-releasing hormone upon sleep-related growth hormone surge
and sleep EEG in man. Neuroendocrinology 48, 32–38. doi: 10.1159/000124986
Houtepen, L. C., Peterse, D. P., Westphal, K. G., Olivier, B., and Vinkers,
C. H. (2011). The autonomic stress-induced hyperthermia response is not
enhanced by several anxiogenic drugs. Physiol. Behav. 102, 105–109. doi:
10.1016/j.physbeh.2010.09.002
Kimura, M., Müller-Preuss, P., Lu, A., Wiesner, E., Flachskamm, C., Wurst, W.,
et al. (2010). Conditional corticotropin-releasing hormone overexpression in
the mouse forebrain enhances rapid eye movement sleep. Mol. Psychiatry 15,
154–165. doi: 10.1038/mp.2009.46
Koob, G., and Bloom, F. (1985). Corticotropin-releasing factor and behavior. Fed.
Proc. 44, 259–263. doi: 10.1016/b978-0-12-532102-0.50007-3
Koob, G. F. (1999). Corticotropin-releasing factor, norepinephrine, and stress. Biol.
Psychiatry 46, 1167–1180. doi: 10.1016/S0006-3223(99)00164-X
Koob, G. F., and Heinrichs, S. C. (1999). A role for corticotropin releasing factor
and urocortin in behavioral responses to stressors. Brain Res. 848, 141–152. doi:
10.1016/S0006-8993(99)01991-5
Krarup, A., Chattopadhyay, P., Bhattacharjee, A. K., Burge, J. R., and Ruble,
G. R. (1999). Evaluation of surrogate markers of impending death in the
galactosamine-sensitized murine model of bacterial endotoxemia. Lab. Anim.
Sci. 49, 545–550.
Lavie, P. (2001). Sleep disturbances in the wake of traumatic events.N. Engl. J. Med.
345, 1825–1832. doi: 10.1056/NEJMra012893
Liu, X. D., Fan, H. K., Zhang, G. H., Wang, S. C., Zhang, Z., and Feng, P. F. (2010).
[Effects of CRF receptor antagonist on rem sleep in neonatal rat]. Zhongguo
Ying Yong Sheng Li Xue Za Zhi 26, 86–89.
Liu, X., Tang, X., and Sanford, L. D. (2003). Fear-conditioned suppression of REM
sleep: relationship to Fos expression patterns in limbic and brainstem regions
in BALB/cJ mice. Brain Res. 991, 1–17. doi: 10.1016/j.brainres.2003.07.003
Liu, X., Tang, X., and Sanford, L. D. (2009). Stressor controllability and Fos
expression in stress regulatory regions in mice. Physiol. Behav. 97, 321–326. doi:
10.1016/j.physbeh.2009.02.038
Machida, M., Yang, L., Wellman, L. L., and Sanford, L. D. (2013). Effects of stressor
predictability on escape learning and sleep in mice. Sleep 36, 421–430. doi:
10.5665/sleep.2464
Frontiers in Neuroscience | www.frontiersin.org 11 July 2015 | Volume 9 | Article 258
Wellman et al. CRF, stress and sleep
Marrosu, F., Gessa, G. L., Giagheddu, M., and Fratta, W. (1990). Corticotropin-
releasing factor (CRF) increases paradoxical sleep (PS) rebound in PS-deprived
rats. Brain Res. 515, 315–318. doi: 10.1016/0006-8993(90)90614-H
Meerlo, P., Easton, A., Bergmann, B. M., and Turek, F. W. (2001). Restraint
increases prolactin and REM sleep in C57BL/6J mice but not in BALB/cJ mice.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 281, R846–R854.
Mellman, T. A., Bustamante, V., Fins, A. I., Pigeon, W. R., and Nolan, B. (2002).
REM sleep and the early development of posttraumatic stress disorder. Am. J.
Psychiatry 159, 1696–1701. doi: 10.1176/appi.ajp.159.10.1696
Mellman, T. A., Pigeon, W. R., Nowell, P. D., and Nolan, B. (2007). Relationships
between REM sleep findings and PTSD symptoms during the early aftermath
of trauma. J. Trauma. Stress. 20, 893–901. doi: 10.1002/jts.20246
Morimoto, A., Nakamori, T., Morimoto, K., Tan, N., and Murakami, N. (1993).
The central role of corticotrophin-releasing factor (CRF-41) in psychological
stress in rats. J. Physiol. 460, 221–229. doi: 10.1113/jphysiol.1993.sp019468
Nakamori, T., Morimoto, A., and Murakami, N. (1993). Effect of a central CRF
antagonist on cardiovascular and thermoregulatory responses induced by stress
or IL-1 beta. Am. J. Physiol. 265, R834–R839.
Neylan, T. C., Otte, C., Yehuda, R., and Marmar, C. R. (2006). Neuroendocrine
regulation of sleep disturbances in PTSD. Ann. N. Y. Acad. Sci. 1071, 203–215.
doi: 10.1196/annals.1364.015
Nishida, M., Pearsall, J., Buckner, R. L., and Walker, M. P. (2009). REM sleep,
prefrontal theta, and the consolidation of human emotional memory. Cereb.
Cortex 19, 1158–1166. doi: 10.1093/cercor/bhn155
Opp, M. R. (1995). Corticotropin-releasing hormone involvement in stressor-
induced alterations in sleep and in the regulation of waking. Adv.
Neuroimmunol. 5, 127–143. doi: 10.1016/0960-5428(95)00004-L
Opp, M. R. (1997). Rat strain differences suggest a role for corticotropin-releasing
hormone in modulating sleep. Physiol. Behav. 63, 67–74. doi: 10.1016/S0031-
9384(97)00390-9
Pawlyk, A. C., Jha, S. K., Brennan, F. X., Morrison, A. R., and Ross, R. J.
(2005). A rodent model of sleep disturbances in posttraumatic stress disorder:
the role of context after fear conditioning. Biol. Psychiatry 57, 268–277. doi:
10.1016/j.biopsych.2004.11.008
Rampin, C., Cespuglio, R., Chastrette, N., and Jouvet, M. (1991). Immobilisation
stress induces a paradoxical sleep rebound in rat. Neurosci. Lett. 126, 113–118.
doi: 10.1016/0304-3940(91)90532-X
Richardson, G. S., and Roth, T. (2001). Future directions in the management of
insomnia. J. Clin. Psychiatry 62, 39–45.
Romanowski, C. P., Fenzl, T., Flachskamm, C., Wurst, W., Holsboer, F., Deussing,
J. M., et al. (2010). Central deficiency of corticotropin-releasing hormone
receptor type 1 (CRH-R1) abolishes effects of CRH on NREM but not on REM
sleep in mice. Sleep 33, 427–436.
Sanford, L. D., Fang, J., and Tang, X. (2003a). Sleep after differing amounts of
conditioned fear training in BALB/cJ mice. Behav. Brain Res. 147, 193–202. doi:
10.1016/S0166-4328(03)00180-3
Sanford, L. D., Tang, X., Ross, R. J., andMorrison, A. R. (2003b). Influence of shock
training and explicit fear-conditioned cues on sleep architecture in mice: strain
comparison. Behav. Genet. 33, 43–58. doi: 10.1023/A:1021051516829
Sanford, L. D., Yang, L., and Tang, X. (2003c). Influence of contextual fear on sleep
in mice: a strain comparison. Sleep 26, 527–540.
Sanford, L. D., Yang, L.,Wellman, L. L., Dong, E., and Tang, X. (2008).Mouse strain
differences in the effects of corticotropin releasing hormone (CRH) on sleep
and wakefulness. Brain Res. 1190, 94–104. doi: 10.1016/j.brainres.2007.11.007
Sanford, L. D., Yang, L., Wellman, L. L., Liu, X., and Tang, X. (2010). Differential
effects of controllable and uncontrollable footshock stress on sleep in mice.
Sleep 33, 621–630.
Sautter, F. J., Bissette, G., Wiley, J., Manguno-Mire, G., Schoenbachler, B.,
Myers, L., et al. (2003). Corticotropin-releasing factor in posttraumatic stress
disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and
healthy control subjects. Biol. Psychiatry 54, 1382–1388. doi: 10.1016/S0006-
3223(03)00571-7
Schüssler, P., Yassouridis, A., Uhr, M., Kluge, M., Weikel, J., Holsboer,
F., et al. (2006). Growth hormone-releasing hormone and corticotropin-
releasing hormone enhance non-rapid-eye-movement sleep after sleep
deprivation. Am. J. Physiol. Endocrinol. Metab. 291, E549–E556. doi:
10.1152/ajpendo.00641.2005
Shors, T. J., Seib, T. B., Levine, S., and Thompson, R. F. (1989). Inescapable versus
escapable shock modulates long-term potentiation in the rat hippocampus.
Science 244, 224–226. doi: 10.1126/science.2704997
Singer, R., Harker, C. T., Vander, A. J., and Kluger, M. J. (1986). Hyperthermia
induced by open-field stress is blocked by salicylate. Physiol. Behav. 36,
1179–1182. doi: 10.1016/0031-9384(86)90497-X
Spina, M. G., Basso, A. M., Zorrilla, E. P., Heyser, C. J., Rivier, J., Vale, W., et al.
(2000). Behavioral effects of central administration of the novel CRF antagonist
astressin in rats. Neuropsychopharmacology 22, 230–239. doi: 10.1016/S0893-
133X(99)00108-6
Swerdlow, N., Geyer, M., Vale, W., and Koob, G. (1986). Corticotropin-releasing
factor potentiates acoustic startle in rats: blockade by chlordiazepoxide.
Psychopharmacology 88, 147–152. doi: 10.1007/BF00652231
Tang, X., and Sanford, L. D. (2002). Telemetric recording of sleep and home cage
activity in mice. Sleep 25, 691–699.
Tang, X., Yang, L., and Sanford, L. D. (2007). Interactions between brief restraint,
novelty and footshock stress on subsequent sleep and EEG power in rats. Brain
Res. 1142, 110–118. doi: 10.1016/j.brainres.2007.01.029
van Bogaert, M. J., Groenink, L., Oosting, R. S., Westphal, K. G., van der Gugten,
J., and Olivier, B. (2006). Mouse strain differences in autonomic responses
to stress. Genes Brain Behav. 5, 139–149. doi: 10.1111/j.1601-183X.2005.
00143.x
Veening, J. G., Bouwknecht, J. A., Joosten, H. J., Dederen, P. J., Zethof,
T. J., Groenink, L., et al. (2004). Stress-induced hyperthermia in the
mouse: c-fos expression, corticosterone and temperature changes.
Prog. Neuropsychopharmacol. Biol. Psychiatry 28, 699–707. doi:
10.1016/j.pnpbp.2004.05.007
Vgontzas, A. N., Bixler, E. O., Lin, H. M., Prolo, P., Mastorakos, G.,
Vela-Bueno, A., et al. (2001). Chronic insomnia is associated with
nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical
implications. J. Clin. Endocrinol. Metab. 86, 3787–3794. doi: 10.1210/jcem.86.
8.7778
Vinckers, C. H., van Oorschot, R., Olivier, B., and Groenink, L. (2009). “Stress-
induced hyperthermia in the mouse. Mood and Anxiety-related Phenotypes,”
in Mice: Characterization Using Behavioral Tests, ed T. D. Gould (New York,
NY: Humana Press), 139–152. doi: 10.1007/978-1-60761-303-9_8
Walker, M. P. (2009). The role of sleep in cognition and emotion. Ann. N. Y. Acad.
Sci. 1156, 168–197. doi: 10.1111/j.1749-6632.2009.04416.x
Wellman, L. L., Fitzpatrick, M. E., Machida, M., and Sanford, L. D. (2014). The
basolateral amygdala determines the effects of fear memory on sleep in an
animal model of PTSD. Exp. Brain Res. 232, 1555–1565. doi: 10.1007/s00221-
014-3850-z
Wellman, L. L., Holbrook, B. D., Yang, L., Tang, X., and Sanford, L. D. (2008).
Contextual fear extinction eliminates sleep disturbances found following fear
conditioning in rats. Sleep 31, 1035–1042.
Wellman, L. L., Yang, L., Ambrozewicz, M. A., Machida, M., and Sanford,
L. D. (2013). Basolateral amygdala and the regulation of fear-conditioned
changes in sleep: role of corticotropin-releasing factor. Sleep 36, 471–480. doi:
10.5665/sleep.2526
Yang, L., Tang, X., Wellman, L. L., Liu, X., and Sanford, L. D. (2009). Corticotropin
releasing factor (CRF) modulates fear-induced alterations in sleep in mice.
Brain Res. 1276, 112–122. doi: 10.1016/j.brainres.2009.04.017
Yang, L., Wellman, L. L., Ambrozewicz, M. A., and Sanford, L. D. (2011a). Effects
of stressor predictability and controllability on sleep, temperature, and fear
behavior in mice. Sleep 34, 759–771. doi: 10.5665/sleep.1044
Yang, L., Wellman, L. L., Tang, X., and Sanford, L. D. (2011b). Effects of
corticotropin releasing factor (CRF) on sleep and body temperature following
controllable footshock stress in mice. Physiol. Behav. 104, 886–892. doi:
10.1016/j.physbeh.2011.05.025
Zethof, T. J., Van der Heyden, J. A., Tolboom, J. T., and Olivier, B. (1994). Stress-
induced hyperthermia in mice: a methodological study. Physiol. Behav. 55,
109–115. doi: 10.1016/0031-9384(94)90017-5
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Wellman, Yang and Sanford. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 12 July 2015 | Volume 9 | Article 258
